GSK plc (LON:GSK) Given Average Recommendation of “Hold” by Analysts

Shares of GSK plc (LON:GSK) have earned a consensus recommendation of “Hold” from the seven ratings firms that are currently covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, four have given a hold recommendation and two have assigned a buy recommendation to the company. The average twelve-month target price among brokers that have covered the stock in the last year is GBX 2,048.57.

Several equities research analysts have issued reports on GSK shares. Citigroup dropped their target price on GSK from GBX 2,250 to GBX 2,100 and set a “neutral” rating on the stock in a research report on Wednesday, May 6th. Jefferies Financial Group reiterated a “buy” rating and issued a GBX 2,500 price target on shares of GSK in a research report on Wednesday, July 29th. Finally, Deutsche Bank Aktiengesellschaft reiterated a “hold” rating and set a GBX 2,000 price objective on shares of GSK in a research note on Tuesday, August 4th.

GSK Stock Performance

Shares of GSK stock opened at GBX 1,917.43 on Tuesday. The stock has a market capitalization of £76.80 billion, a P/E ratio of 16.28, a PEG ratio of 1.24 and a beta of 0.29. The company has a current ratio of 0.82, a quick ratio of 0.73 and a debt-to-equity ratio of 103.36. The firm’s 50 day moving average is GBX 1,941.69 and its 200 day moving average is GBX 1,996.20. GSK has a 12 month low of GBX 1,288.61 and a 12 month high of GBX 2,282.

GSK (LON:GSK) last released its quarterly earnings data on Tuesday, July 28th. The company reported GBX 10.80 earnings per share for the quarter. GSK had a net margin of 14.52% and a return on equity of 28.35%. On average, sell-side analysts anticipate that GSK will post 175.980975 earnings per share for the current year.

Insider Buying and Selling at GSK

In other news, insider Jonathan Symonds purchased 1,550 shares of the stock in a transaction dated Friday, June 19th. The shares were purchased at an average cost of GBX 1,935 per share, with a total value of £29,992.50. Also, insider Vishal Sikka purchased 1,266 shares of the stock in a transaction dated Monday, June 22nd. The stock was purchased at an average cost of GBX 5,069 per share, for a total transaction of £64,173.54. Insiders purchased 3,618 shares of company stock valued at $13,481,942 in the last quarter. 0.20% of the stock is currently owned by corporate insiders.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections.